Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Medical College of Wisconsin
Merck Sharp & Dohme LLC
University of Erlangen-Nürnberg Medical School
University of Kentucky
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of Texas Southwestern Medical Center
University of California, San Diego
Mayo Clinic
MacroGenics
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Flamingo Therapeutics NV
University of California, Davis
Emory University
University of Michigan Rogel Cancer Center
Royal Marsden NHS Foundation Trust
Radiation Therapy Oncology Group
University of Pittsburgh
Merck Sharp & Dohme LLC
Incyte Corporation
Wake Forest University Health Sciences
Gilead Sciences
Washington University School of Medicine
Medical University of South Carolina
Dana-Farber Cancer Institute
University of Southern California
M.D. Anderson Cancer Center
EMD Serono
Sanofi
Hoffmann-La Roche
University of Arkansas
Incyte Corporation
GERCOR - Multidisciplinary Oncology Cooperative Group
Yale University
University of California, San Diego
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Formation Biologics
Nektar Therapeutics
NGM Biopharmaceuticals, Inc
Numab Therapeutics AG
M.D. Anderson Cancer Center
University of Chicago